Peter Hodson Oncolytics Biotech ONC-T COMMENT Feb 19, 2007

Phase 2 cancer company with some pretty decent results. They are a long way away from where they want to be. Product has huge potential.

Peter Hodson

Unlock Rating

$2.410

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

WEAK BUY

Interesting technology. Trials are turning out well, but too small a sampling at this time. Speculative.

WEAK BUY

Biotechs have had good moves. Has a ways to go before their drug is on the market. Speculative in the short term.

WEAK BUY

A wild stock. Created a virus that could reduce cancer dramatically. Long term potential could be good. Trials have only been small ones. Risky.

DON'T BUY

If they can find the right deals and get through the clinical trials, the upside would be phenomenal. Very volatile right now.

WAIT

Has a pretty high beta, so the stock goes up and down like a yo-yo. Likes with the company is doing. At some point, a major pharmaceutical company will get interested in their technology. Would like to see more trials and results.

WEAK BUY

Not aware of any upcoming short term catalysts. Continuing with their trials. Never had bad results. Very volatile and still early stage.

DON'T BUY

The technicals do not look good at all – with a decline lasting over the past two months. He would not touch this one at all. A 50 day moving average would be a buy signal if it can trade back above it.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Peter Hodson Oncolytics Biotech ONC-T COMMENT Feb 19, 2007

You might be interested:

Oncolytics Biotech(ONC-T)

Oncolytics Biotech(ONC-T)

Oncolytics Biotech(ONC-T)

Oncolytics Biotech(ONC-T)

Oncolytics Biotech(ONC-T)

Oncolytics Biotech(ONC-T)

Oncolytics Biotech(ONC-T)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Chris Blumas

Stockchase Insights

Jim Cramer - Mad Money

Eric Nuttall

The Panic-Proof Portfolio (Stockchase Research)